Characterized by its dual function as a classical aerobic glycolytic enzyme and a non-metabolic protein kinase-like entity in HCC cells, PKM2 has emerged as a critical therapeutic target, with numerous bioactive molecules demonstrating efficacy in suppressing HCC progression. Here, PKM is linked to hepatocellular carcinoma.